Hjem › Akut myelogen leukemi › Washington › Seattle
Kliniske studier for Akut myelogen leukemi i Seattle, WA
40 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Seattle (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- og 1 flere
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Swedish Medical Center-First Hill, Seattle
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RekruttererFase 3
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruttererFase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Swedish Medical Center-First Hill, Seattle
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Swedish Medical Center-First Hill, Seattle
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
RekruttererFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RekruttererFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Rekrutterer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruttererFase 3
- Seattle Children's Hospital, Seattle
A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant
Rekrutterer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
- Seattle Children's Hospital, Seattle
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RekruttererFase 3
- Seattle Children's Hospital, Seattle
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- University of Washington, Seattle
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Rekrutterer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
RekruttererFase 2
- Fred Hutchinson Cancer Center/University of Washington Cancer Consortium, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
RekruttererFase 2
- Fred Hutchinson Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- Fred Hutchinson Cancer Research Center, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RekruttererFase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RekruttererFase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RekruttererFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
RekruttererFase 1/2Frivillige helsepersonell ønskes velkommen
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruttererFase 2/3
- Seattle Cancer Care Alliance, Seattle
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
RekruttererFase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
RekruttererFase 1/2
- Fred Hutchinson Cancer Center, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RekruttererFase 2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
RekruttererFase 1
- Seattle Children's Hospital, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
RekruttererFase 2
- Fred Hutchinson Cancer Research Center, Seattle
Novel Digital Application for Patients With Acute Leukemia
Rekrutterer
- Fred Hutchinson Cancer Research Center (FHCRC), Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
RekruttererFrivillige helsepersonell ønskes velkommen
- Fred Hutchinson Cancer Center, Seattle
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
Akut myelogen leukemi-studier i andre byer
- Houston, TX85 studier
- New York City, NY51 studier
- Boston, MA44 studier
- Baldwin Park, CA40 studier
- Columbus, OH35 studier
- Philadelphia, PA34 studier
- Durham, NC33 studier
- Atlanta, GA30 studier
- Tampa, FL29 studier
- Chicago, IL26 studier
- Portland, OR25 studier
- Miami, FL24 studier
Andre studier i Seattle
- Ikke-småcellet lungekreft53 studier
- Kreft (alle typer)49 studier
- Prostatakreft42 studier
- Brystkreft39 studier
- Metastatisk kreft39 studier
- Kolorektal kreft34 studier
- Lungekreft33 studier
- Eggstokkreft30 studier
- Multipelt myelom22 studier
- Myelodysplastiske syndromer21 studier
- Akut lymfoblastisk leukemi21 studier
- Blærekreft21 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.